Literature DB >> 17296334

Determination of lidocaine and its two N-desethylated metabolites in dog and horse plasma by high-performance liquid chromatography combined with electrospray ionization tandem mass spectrometry.

A Maes1, L Weiland, C Sandersen, F Gasthuys, P De Backer, S Croubels.   

Abstract

A sensitive method for the quantification of lidocaine and its metabolites, monoethylglycinexylidide (MEGX) and glycinexylidide (GX), in animal plasma using high-performance liquid chromatography combined with electrospray ionization mass spectrometry is described. The sample preparation includes a liquid-liquid extraction with methyl tert-butylmethyl ether after addition of 2M sodium hydroxide. Ethylmethylglycinexylidide (EMGX) is used as an internal standard. For chromatographic separation, an ODS Hypersil column was used. Isocratic elution was achieved with 0.01 M ammonium acetate and acetonitrile as mobile phases. Good linearity was observed in the range of 2.5-1000 ng ml(-1) for lidocaine in both dog and horse plasma. For MEGX, linear calibration curves were obtained in the range of 5-1000 ng ml(-1) and 20-1000 ng ml(-1) for dog and horse plasma, respectively. In dog and horse plasma good linearity was observed in the range of 200-1500 ng ml(-1) for GX. The limit of quantification (LOQ) in dog plasma for lidocaine, MEGX and GX was set at 2.5 ng ml(-1), 20 ng ml(-1) and 200 ng ml(-1), respectively. For horse plasma a limit of quantification of 2.5 ng ml(-1), 5 ng ml(-1) and 200 ng ml(-1) was achieved for lidocaine, MEGX and GX, respectively. In dog plasma, the limit of detection (LOD) was found to be 0.8 ng ml(-1), 2.3 ng ml(-1) and 55 ng ml(-1) for lidocaine, MEGX and GX, respectively. In horse plasma the LOD's found for lidocaine, MEGX and GX, were 1.1 ng ml(-1), 0.5 ng ml(-1) and 13 ng ml(-1), respectively. The method was shown to be of use in pharmacokinetic studies after application of a transdermal patch in dogs and after an intravenous infusion in horses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17296334     DOI: 10.1016/j.jchromb.2007.01.010

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  4 in total

1.  The Oral Administration of Lidocaine HCl Biodegradable Microspheres: Formulation and Optimization.

Authors:  Bushra T ALQuadeib; Eram Kd Eltahir; Modhi F Alagili
Journal:  Int J Nanomedicine       Date:  2020-02-05

2.  Investigation of the Inhibitory Effect of Simvastatin on the Metabolism of Lidocaine Both in vitro and in vivo.

Authors:  Ying Wang; Qiu-Geng Ou-Yang; Wan-Li Huang; Huan-le Huang; Xin-Lei Zhuang; Qian-Meng Lin; Da-Li Zeng
Journal:  Drug Des Devel Ther       Date:  2020-05-06       Impact factor: 4.162

3.  Evaluation of Lidocaine and Metabolite Pharmacokinetics in Hyaluronic Acid Injection.

Authors:  Ju Hee Kim; Dong Wook Kang; Go-Wun Choi; Sang Bok Lee; Seongjin Lee; Hea-Young Cho
Journal:  Pharmaceutics       Date:  2021-02-02       Impact factor: 6.321

4.  Evaluation of serum lidocaine/monoethylglycylxylidide concentration to assess shunt closure in dogs with extrahepatic portosystemic shunts.

Authors:  Nausikaa Devriendt; Gonçalo Serrano; Siska Croubels; Emmelie Stock; Eva Vandermeulen; Dominique Paepe; Jennifer von Luckner; Hilde de Rooster
Journal:  J Vet Intern Med       Date:  2021-01-12       Impact factor: 3.175

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.